NASDAQ:ARMO ARMO BioSciences (ARMO) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ARMO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$49.98▼$49.9850-Day Range$49.98▼$49.9852-Week Range$25.10▼$57.19VolumeN/AAverage Volume201,363 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ARMO BioSciences alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About ARMO BioSciences Stock (NASDAQ:ARMO)ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… ARMO Stock News HeadlinesApril 22, 2024 | msn.comFF16: All New Items Introduced In The Rising Tide DLCApril 21, 2024 | msn.comFinal Fantasy 16: All New Gear in The Rising Tide (& Where to Find It)April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 3, 2024 | morningstar.comPacific Biosciences of California IncDecember 1, 2023 | msn.comPedro Pascal Gets Realistic Fantastic Four Armor As Reed Richards In Stunning MCU ArtNovember 6, 2023 | finance.yahoo.comCaribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory BoardOctober 14, 2023 | msn.com5 Sizzling Well-Known Stocks Under $10 With Giant Upside PotentialJuly 21, 2023 | forbes.comArmor Protective PackagingApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 28, 2023 | msn.comBest Armor Sets In V Rising, RankedMay 11, 2023 | investing.comCodiak BioSciences Inc (CDAKQ)February 18, 2023 | msn.comPedro Pascal Has A Candid Confession About The Mandalorian ArmorFebruary 15, 2023 | msn.comPedro Pascal's Mandalorian Suit Is Way Clumsier To Wear In Real-Life Than On TVFebruary 14, 2023 | msn.comPedro Pascal Gets Asked About What It's Like To Wear The Mandalorian Armor And Gave A Very Honest ResponseJanuary 22, 2023 | finance.yahoo.comNovadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical OfficerJanuary 12, 2023 | finance.yahoo.comBoehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer ImmunotherapiesJanuary 2, 2023 | msn.comHow To Find All Wraith Lairs In Immortals Fenyx RisingDecember 14, 2022 | marketwatch.comMyocarditis Treatment Market Growth Share 2023 | Research by Future Prospects, Opportunities and Challenges, Key Dynamics and Size Forecast to 2028August 19, 2022 | chron.comTexas company hopes to 'de-extinct' Tasmanian tiger in next 10 yearsAugust 18, 2022 | nz.finance.yahoo.comHR Acuity Named to Inc. 5000 Annual ListAugust 13, 2022 | reuters.comEli Lilly and CoAugust 8, 2022 | businessinsider.com9 top West Coast biotechs that VCs say are poised to take off in the next yearAugust 2, 2022 | entrepreneur.com2 Stocks That Could Be Long-Term Winners for InvestorsJuly 19, 2022 | finance.yahoo.comInsilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee Clinical DevelopmentJuly 14, 2022 | msn.comHow to craft Hollowfang Battlegear in V RisingJuly 11, 2022 | msn.comHow To Farm Pristine Hide In V RisingJuly 8, 2022 | msn.comMetal Gear Rising: Revengeance - How To Beat GRADSee More Headlines Receive ARMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARMO BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/02/2018Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ARMO CUSIPN/A CIK1693664 Webwww.armobio.com Phone650-779-5075FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Peter Van Vlasselaer (Age 59)Founder, Pres, CEO & Director Mr. Herbert C. Cross (Age 46)Chief Financial Officer Dr. Joseph Leveque (Age 57)Chief Medical Officer Dr. Martin Oft (Age 51)Founder and VP of Pre-Clinical & Clinical Devel. Dr. Russell T. Kawahata (Age 64)VP of Technical Operations Key CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors ARMO Stock Analysis - Frequently Asked Questions How were ARMO BioSciences' earnings last quarter? ARMO BioSciences, Inc. (NASDAQ:ARMO) issued its earnings results on Monday, April, 2nd. The company reported ($9.62) EPS for the quarter, missing the consensus estimate of ($0.45) by $9.17. What other stocks do shareholders of ARMO BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ARMO BioSciences investors own include Standex International (SXI), Exelixis (EXEL), Tesla (TSLA), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Bausch Health Companies (BHC), EyePoint Pharmaceuticals (EYPT), Madrigal Pharmaceuticals (MDGL) and Progenics Pharmaceuticals (PGNX). When did ARMO BioSciences IPO? ARMO BioSciences (ARMO) raised $100 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Baird was co-manager. This page (NASDAQ:ARMO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARMO BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
